June 4, 2021Open Access

Sotorasib para Cânceres de Pulmão com Mutação KRAS p.G12C

Key Points

Key points are not available for this paper at this time.

Abstract

Neste ensaio de fase 2, a terapia com sotorasib resultou em um benefício clínico duradouro sem novos sinais de segurança em pacientes com NSCLC mutado KRAS p.G12C previamente tratados. (Financiado pela Amgen e pelos Institutos Nacionais de Saúde; CodeBreaK100 ClinicalTrials.gov número, NCT03600883.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Ferdinandos Skoulidis

Bob T. Li

Grace K. Dy

Journals

New England Journal of Medicine

Actions

Institutions

Johns Hopkins University

Cornell University

New York University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Sotorasib para Cânceres de Pulmão com Mutação KRAS p.G12C

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider